Bladder Cancer Epidemiology Insights

Thelansis’s “Bladder Cancer Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.

Bladder Cancer Overview

Bladder cancer is the most common malignancy of the urinary tract, with urothelial carcinoma representing the predominant histological subtype, arising from the transitional epithelium lining the bladder mucosa. Tobacco smoking, occupational aromatic amine exposure, chronic bladder inflammation, and cyclophosphamide exposure are established risk factors, with somatic mutations in FGFR3, TP53, RB1, and PIK3CA driving oncogenic transformation across non-muscle-invasive and muscle-invasive disease spectrums. Patients present with painless macroscopic haematuria — the cardinal symptom — alongside urinary frequency, urgency, and dysuria; cystoscopy with biopsy remains the diagnostic gold standard, supplemented by upper tract imaging and CT urography. Non-muscle-invasive bladder cancer is managed endoscopically via transurethral resection, with intravesical BCG immunotherapy reducing recurrence and progression risk in high-risk disease; pembrolizumab is approved for BCG-unresponsive carcinoma in situ. Muscle-invasive disease warrants neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or bladder-preserving trimodality therapy. Metastatic disease is addressed with platinum-based chemotherapy, while maintenance avelumab immunotherapy following platinum response has demonstrated meaningful survival benefit. Erdafitinib targets FGFR3-altered metastatic disease, and enfortumab vedotin — a Nectin-4 directed antibody-drug conjugate — alongside pembrolizumab represents a transformative first-line metastatic standard. Prognosis varies with stage; multidisciplinary management, surveillance cystoscopy, and patient-centred quality-of-life optimisation are integral to long-term care.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Deliverables format and updates*:

• Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
• Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

• 20-year historical and forecast data (2020–2040)
• Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
• Granular patient population coverage by year and geography
• Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
• Patient funnels
• Country comparisons
• Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

• Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
• Primary market research with KOLs
• RWD analysis using claims and EHR datasets
• Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)